Valuation: Cytori Therapeutics Inc

Market Cap 5.36M 4.89M 4.52M 4.08M 7.69M 501M 7.99M 54.63M 21.6M 271M 20.12M 19.7M 854M P/E 2026 *
-0.16x
P/E 2027 * -0.19x
Enterprise Value 5.36M 4.89M 4.52M 4.08M 7.69M 501M 7.99M 54.63M 21.6M 271M 20.12M 19.7M 854M EV / Sales 2026 *
1.33x
EV / Sales 2027 * 0.39x
Free-Float
75.98%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 64 02/04/2014
Director of Finance/CFO 52 06/02/2020
Chief Operating Officer 53 06/11/2026
Director TitleAgeSince
Director/Board Member 64 01/10/2002
Chairman 77 25/01/2018
Director/Board Member 66 01/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
-1.34%-3.09%+56.10%+68.83% 65.45B
-0.93%-3.97%+6.77%+88.91% 58.93B
+0.59%+0.60%+26.51%+87.57% 55.21B
-2.34%-3.90%+10.90%+115.97% 46.1B
+0.09%-6.08%+18.67%+25.90% 42.49B
-2.58%+0.24%+18.54%+41.28% 35.56B
-1.76%-11.56%+126.44%+649.27% 34.57B
-0.06%-1.02%+76.55%+57.39% 32.46B
-1.69%-0.79%-40.58%+382.68% 26.28B
Average -1.11%-3.40%+33.32%+168.64% 44B
Weighted average by Cap. -1.04%-3.29%+33.44%+143.20%

Financials

2026 *2027 *
Net sales 4.04M 3.69M 3.41M 3.08M 5.79M 378M 6.02M 41.15M 16.27M 204M 15.16M 14.84M 644M 13.85M 12.63M 11.68M 10.54M 19.85M 1.29B 20.63M 141M 55.75M 699M 51.95M 50.87M 2.21B
Net income -31.67M -28.89M -26.71M -24.1M -45.39M -2.96B -47.18M -323M -128M -1.6B -119M -116M -5.04B -29.66M -27.05M -25.01M -22.57M -42.51M -2.77B -44.19M -302M -119M -1.5B -111M -109M -4.72B
Net Debt - -
Logo Cytori Therapeutics Inc
Cerenome, Inc., formerly Plus Therapeutics, Inc., is a healthcare company. The Company is focused on central nervous system (CNS) cancers through three business areas: precision diagnostics, targeted radiopharmaceutical therapeutics, and proprietary data analytics. Its subsidiary CNSide Diagnostics, LLC, develops and commercializes proprietary laboratory-developed tests, including the CNSide cerebrospinal fluid (CSF) assay platform, designed to identify, characterize and monitor tumor cells in patients with CNS cancers. Its lead product candidate, rhenium (186Re) obisbemeda (REYOBIQ), is designed for CNS cancers, including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC), through direct localized delivery utilizing tissue access methods, including convection-enhanced delivery (CED) and others. Its Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM), is designed to treat primary and metastatic solid organ cancers.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Cytori Therapeutics Inc